Effects of ovariectomy and tamoxifen on rat bone tissue: Histomorphometric and histopathologic study

Analytical and Quantitative Cytology and Histology

Volumn 28, Issue 4, 2006, Pages 207-212

  Aktug, Hüseyin ^a,b   Uslu, Serap ^a   Terek, Mustafa Coşan ^a   Terzi, Hasan ^a   Turgut, Mehmet ^a   Özşener, Serdar ^a   Bilgin, Onur ^a  

^a Department of Histology and Embryology ^*

^b EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Bone; Histology; Histomorphology; Ovariectomy; Tamoxifen

Indexed keywords

ANTIESTROGEN; DIMETHYL SULFOXIDE; TAMOXIFEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITOMETRY; BONE DISEASE; BONE TISSUE; CELL COUNT; CELL PROLIFERATION; CONTROLLED STUDY; CORTICAL BONE; EQUIPMENT; ESTROGEN ACTIVITY; FEMALE; FEMUR; HISTOLOGY; HISTOPATHOLOGY; LUMBAR VERTEBRA; MICROTOME; MORPHOMETRICS; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OVARIECTOMY; PRIORITY JOURNAL; RAT; TRABECULAR BONE;

ANIMALS; BONE AND BONES; BONE DENSITY; FEMALE; FEMUR; LUMBAR VERTEBRAE; OSTEOGENESIS; OVARIECTOMY; RATS; RATS, SPRAGUE-DAWLEY; TAMOXIFEN;

EID: 33746708119     PISSN: 08846812     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Jordan VC, Murphy CS: Endocrine pharmacology of antiestrogens as antitumor agents. Endocrin Rev 1990;11:578-610
2. Love RR, Mazess RB, Bardon HS, Epstein S, Newcomb PA, Jordan VC, Carbone PP, DeMets DL: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1991;326:852-856
3. Prentice RL: Tamoxifen as a potential preventive agent in healthy postmenopausal women. J Nat Cancer Inst 1990;82: 1310-1311
4. Nicholson RI, Gee JM, Bryant S, Francis AB, McClelland RA, Knowlden J, Wakeling AE, Osborne CK: Pure antiestrogens: The most important advance in the endocrine therapy of breast cancer since 1896. Ann N Y Acad Sci 1996;784:325-335
5. Kangas L: Development and biochemical pharmacology of toremifene, an antiestrogenic antitumor drug. Acta Obstet Gynecol Scand 1991;70:399
6. Baker VL, Jaffe RB: Clinical uses of antiestrogens. Obstet Gynecol Surv 1996;51:45-59
7. Morris HA, Porter SJ, Durbridge TC, Moore RJ, Need AG, Nordin BEC: Effects of ovariectomy on biochemical and bone variables in the rat. Bone Miner 1992;18:133-142
8. Kalu DN, Liu CC, Hardin RR, Hollis BW: The aged rat model of ovarian hormone deficiency bone loss. Endocrinology 1989;124:7-16
9. Lykkesfeldt AE, Larsen SS, Briand P: Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment. Int J Cancer 1995;61:529-534
10. Cui L, Wu T, Liu YY, Deng YF, Ai CM, Chen HQ: Tanshinone prevents cancellous bone loss induced by ovariectomy in rats. Acta Pharmacol Sin 2004;25:678-684
11. Chen JL, Yao W, Frost HM, Li CY, Setterberg RB, Jee WSS: Bipedal stance exercise enhance antiresorption effects of estrogen and counteracts its inhibitory effect on bone formation in sham and ovariectomized rats. Bone 2001;29:126-133
12. Ke HZ, Simmons HA, Pirie CM, Crawford DT, Thompson DD: Droloxifene: A new estrogen antagonist/agonist prevents bone loss in ovariectomized rats. Endocrinology 1995;136:2435-2441
13. Ma YL, Bryant HU, Zeng Q, Schmidt A, Jee WS, Sato M: Raloxifene and teriparatide (hPTH 1-34) have complementary effects on the osteopenic skeleton of ovariectomized rats. J Bone Miner Metab 2005;23:62-68
14. Maxim P, Ettinger P, Spitalny GM: Fracture protection provided by long-term estrogen treatment. Osteoporosis Int 1995;5:23-29
15. Evans GL, Turner RT: Tissue-selective actions of estrogen analogs. Bone 1995;17:181S-190S
16. Kalu DN, Salermo E, Liu CC, Echon R, Ray M, Garza-Zapata M, Hollis BW: A comparative study of the actions of tamoxifen, estrogen and progesterone in the ovariectomized rat. Bone Miner 1991;15:109-124
17. Moon LY, Wakley GK, Turner RT: Dose dependent effects of tamoxifen on long bones of growing rats: Influence of ovarian status. Endocrinology 1991;129:1568-1574
18. Turner RT, Wakley GK, Hannon KS, Bell NH: Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats. J Bone Miner Res 1987;2:449-456
19. Turner RT, Wakley GK, Hannon KS, Bell NH: Tamoxifen inhibits osteoclast mediated resorption of trabecular bone in ovarian hormone deficient rats. Endocrinology 1988;122: 1146-1150
20. Bagdade JD, Wolter J, Subbatah PV, Ryan W: Effects of tamoxifen treatment on plasma lipid and lipoprotein lipid compozition. J Clin Endocrinol Metab 1990;70:1132-1135
21. Wakley GK, Baum BL, Hannon KS, Turner RT: The effects of tamoxifen on the osteopenia induced by sciatic neurotomy in the rat: A histomorphometric study. Calcif Tissue Int 1988;43:383-388
22. Zeng QQ, Jee WS, Bigornia AE, King JG, Jr D'Souza SM, Li XJ, Ma YF, Wechter WJ: Time responses of cancellous and cortical bones to sciatic neurectomy in growing female rats. Bone 1996;19:13-21
23. Kedar RP, Bourne TH, Powles TJ, Collins WP, Ashley SE, Cosgrove EXD: Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial. Lancet 1994;343:1318-1321
24. Lahti E, Guillermo B, Kauppila A: Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 1993;81:660-664
25. Berry M, Metzger D, Chambon P: Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the antioestrogen 4-hydroxytamoxifen. EMBO J 1990;9:2811-2818
26. Breitbach GP, Reister C, Droege H, Bastert G: Pharmacokinetics of droloxifene in comparison with tamoxifen. Onkologie 1994;17:49-53
27. Shull JD, Beams FE, Baldwin TM, Gilehrist CA, Hebek MJ: The estrogenic and antiestrogenic properties of tamoxifen in GH4C1 pituitary tumor cells are gene specific. Mol Endocrinol 1992;6:529-535
28. Berry M, Metzger D, Chambon P: Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the antioestrogen 4-hydroxytamoxifen. EMBO J 1990;9:2811-2818
29. Bancroft JD, Gamble M: Theory and Practice of Histological Techniques, New York: Churchill Livingstone, 2001.
30. Hanyu T, Chotanaphuti T, Aral K, Tanaka T, Takahashi HE: Histomorphometric assessment of bone changes in rats with type II collagen-induced arthritis. Bone 1999;24:485-490
31. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ort SM, Recker RR: Bone histomorphometry: Standardization of nomenclature, symbols, and units. J Bone Miner Res 1987;2:595-609
32. Eppenberger U, Wosikowski K, Kung W: Pharmacologic and biologic properties of droloxifene, a new antiestrogen. Am J Clin Oncol 1991;14:S5-S14
33. Turner RT, Wakley GK, Hannon KS, Bell NH: Tamoxifen inhibits osteoclast-mediated resorption of trabecular bone in ovarian hormone deficient rats. Endocrinology 1988;122: 1146-1150
34. Shull JD, Beams FE, Baldwin TM, Gilehrist CA, Hebek MJ: The estrogenic and antiestrogenic properties of tamoxifen in GH4C1 pituitary tumor cells are gene specific. Mol Endocrinol 1992;6:529-535
35. Ke HZ, Chen HK, Qi H, Pirie CM, Simmons HA, Ma YF, Jee WSS, Thompson DD: Effects of droloxifene on prevention of bone loss and bone turnover in the axial skeleton of aged, ovariectomized rats. Bone 1995;17:491-496
36. Chen HK, Ke HZ, Lin CH, Ma YF, Crawford DT, Pirie CM, Simmons HA, Jee WS, Thompson DD: Droloxifene inhibits cortical bone turnover associated with estrogen deficiency in rats. Bone 1995;17:175S-179S
37. Junqueira LC, Carneiro J, Kelley RO: Basic Histology. Norwalk, Connecticut: Appleton & Lange, 1995, pp 124-131
38. Schmidt IU, Wakley GK, Turner RT: Effects of estrogen and progesterone on tibia histomorphometry in growing rats. Calcif Tissue Int 2000;67:47-52